Andreu Fernández-Codina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Andreu Fernández-Codina has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Iago Pinal-Fernandez
Muscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA
9 shared publications - Fernando Martínez-Valle
Medicina Interna, Hospital Vall d'Hebron, Barcelona, España
7 shared publications - Janet Elizabeth Pope
University of Western Ontario, London, Ontario, Canada
7 shared publications - Carmen Pilar Simeón-Aznar
Systemic Autoimmune Diseases Unit, Department of Internal Medicine University Vall d'Hebron Hospital Barcelona Spain
6 shared publications Miquel Vilardell-Tarrés
Systemic Autoimmune Diseases Unit, Internal Medicine Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institute of Research, Universitat Autònoma de Barcelona, Barcelona, Spain
6 shared publications- Albert Selva-O’cAllaghan
Internal Medicine Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona , Barcelona
5 shared publications
Latest Publications
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 28 August 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (11) , 2129-2135
Use of parenteral compared with oral glucocorticoids in early rheumatoid arthritis for chance of being off steroids and escalation of therapy at 1 year
- 24 December 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 20 (3) , 939-940
Acute aortic syndrome as an early complication of giant cell arteritis
- 24 December 2024
- Published by Springer Nature in Internal and Emergency Medicine
- Vol. 20 (3) , 939-940
Acute aortic syndrome as an early complication of giant cell arteritis
- Open Access
- 27 August 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (2) , 888-889
Brentuximab vedotin compared with historical controls for severe skin involvement in cutaneous systemic sclerosis
Andreu Fernández-Codina, Tatiana Nevskaya, Murray Baron, C Thomas Appleton, Matthew J Cecchini, Amanda Philip, Maha El-Shimy, Louise Vanderhoek, Iago Pinal
- 27 August 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (2) , 888-889
Open AccessBrentuximab vedotin compared with historical controls for severe skin involvement in cutaneous systemic sclerosis
Andreu Fernández-Codina, Tatiana Nevskaya, Murray Baron, C Thomas Appleton, Matthew J Cecchini, Amanda Philip, Maha El-Shimy, Louise Vanderhoek, Iago Pinal
- Open Access
- 23 April 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1476-1481
Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial
We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). This phase II proof-of-concept, single centre, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with P = 0.001), meeting the primary end point in the intention to treat analysis (7/11 had a decrease in mRSS ≥8). The % forced vital capacity increased by 7.8% (12.5). The Composite Response Index in dcSSc (CRISS) suggested a beneficial treatment effect (86% ≥0.6). Most adverse events were mild. No SAEs were attributed to brentuximab vedotin. In dcSSc, brentuximab vedotin improved skin and FVC without safety concerns. A placebo-controlled trial is warranted to corroborate these initial findings. ClinicalTrials.gov, http://clinicaltrials.gov, NCT03198689.
- 23 April 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (3) , 1476-1481
Open AccessBrentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial
We explored the efficacy and safety of brentuximab vedotin, a chimeric anti-CD30 antibody drug conjugate, in patients with severe active diffuse cutaneous systemic sclerosis (dcSSc). This phase II proof-of-concept, single centre, open-label, single arm, investigator-initiated trial included patients ≥18 years, with dcSSc, modified Rodnan skin score (mRSS) ≥15 with P = 0.001), meeting the primary end point in the intention to treat analysis (7/11 had a decrease in mRSS ≥8). The % forced vital capacity increased by 7.8% (12.5). The Composite Response Index in dcSSc (CRISS) suggested a beneficial treatment effect (86% ≥0.6). Most adverse events were mild. No SAEs were attributed to brentuximab vedotin. In dcSSc, brentuximab vedotin improved skin and FVC without safety concerns. A placebo-controlled trial is warranted to corroborate these initial findings. ClinicalTrials.gov, http://clinicaltrials.gov, NCT03198689.
- 1 January 2024
- Published by Springer Nature
- p. 317-321
IgG4-Related Disease
- 1 November 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (11)
Ischemic Complications of Giant-Cell Arteritis
- 1 November 2023
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 2 (11)
Ischemic Complications of Giant-Cell Arteritis
- 24 October 2022
- Published by Elsevier in Medicina Clinica
- Vol. 160 (3) , 140-141
Reply
- 9 June 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 158 (10) , 466-471
Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients
- 9 June 2022
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 158 (10) , 466-471
Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients
- 1 May 2022
- Published by Elsevier in Medicina Clinica
- Vol. 158 (10) , 466-471
Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients
- 1 May 2022
- Published by Elsevier in Medicina Clinica
- Vol. 158 (10) , 466-471
Radiography-based triage for COVID-19 in the Emergency Department in a Spanish cohort of patients
- 5 June 2020
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 6 (3) , 191-204
Therapeutic Options in IgG4-Related Disease
- 5 June 2020
- Published by Springer Nature in Current Treatment Options in Rheumatology
- Vol. 6 (3) , 191-204
Therapeutic Options in IgG4-Related Disease